ArterialIntelligence
Vascular diagnostics

Reimagining vascular diagnostics.

A noninvasive, point-of-care Doppler platform designed to support vascular assessment. Arterial Intelligence works independent of pressure ratios and cuff occlusion.

  • 21M+U.S. adults estimated to have peripheral artery disease (PAD)
  • 1/3of PAD patients have arteries too stiff to compress, causing current tests to fail
  • 30%of PAD patients are dead within 5 years because their disease is caught too late
The gap

The gap in vascular diagnostics.

Current screening methods leave room for improvement. The ankle-brachial index is fast and cheap, but for the patients who need it most, it’s also the least reliable.

Unreliable

ABI can miss high-risk patients

In diabetes and chronic kidney disease, ABI alone can return false negatives and delay the next test.

Inconclusive

Calcified arteries break the cuff

Calcification makes arteries noncompressible. The current diagnostic workflow relies on blood pressure, so the test fails.

Too late

Late detection raises the stakes

Found later, vascular disease is associated with worse outcomes and heavier treatment.

Sources: CDC, About PAD; Diabetol Metab Syndr 2024.

Solution

A smarter approach to vascular screening.

As disease narrows an artery, the Doppler waveform downstream changes in a recognizable way, and calcification doesn’t distort it the way it distorts cuff pressure. That’s the signal Arterial Intelligence is built around.

Triphasic

Typical normal

Sharp upstroke, brief reversal, small late forward wave.

Biphasic

Changing

The late forward wave drops out.

Monophasic

Dampened

Slow rise, rounded peak, no reversal.

Waveforms are simplified illustrations, not output from the Arterial Intelligence platform.

How it works

Three steps, one visit.

Designed to support earlier identification and workflow efficiency.

  1. Scan

    A handheld probe captures arterial waveforms in minutes at the point of care. No cuff, no occlusion.

  2. Analyze

    Software-supported waveform interpretation, intended to aid clinical assessment.

  3. Act

    Structured output designed to fit the clinical workflow and help prepare guideline-directed next steps.

Benefits

Designed for clinics, patients, and health systems.

Clinics

  • Fits the visitDesigned to run during an existing appointment.
  • Fast at the point of careWaveform capture in minutes.
  • Built with reimbursement in mindDesigned around established noninvasive vascular testing pathways.
Team

The people behind it.

Experience from
  • Mayo Clinic
  • Stanford Biodesign
  • DARPA
  • Medtronic
  • Abbott
  • Johnson & Johnson
  • Stryker
  • Josh Hanson

    Josh Hanson

    Chief Executive Officer

    Biodesign trained. Mayo Clinic Gonda Vascular Center.

    • Mayo Clinic
    • Stanford Biodesign
  • Alex Richardson

    Alex Richardson

    Chief Technology Officer

    Engineer for DARPA, Medtronic, and Abbott. $100M raised and 3 medtech exits.

    • DARPA
    • Medtronic
    • Abbott
  • Chris Galando

    Chris Galando

    Head of Commercialization

    20+ years in sales leadership. Led cardiovascular sales for J&J and Stryker.

    • Johnson & Johnson
    • Stryker
  • Robert McBane, MD

    Robert McBane, MD

    Chair, Scientific Advisory Board

    25+ years in cardiovascular medicine at Mayo Clinic. 200+ publications. Master of the Society for Vascular Medicine.

    • Mayo Clinic
    • Society for Vascular Medicine
Press

Press and milestones.

Recognition, programs, and stages from 2026.

Award · Sept. 18, 2026 · Newport Beach, CA

People’s Choice Award at Octane’s Cardiovascular Tech Forum

Chosen by an audience vote of physicians, entrepreneurs, investors, and industry leaders after our presentation at the 2026 Cardiovascular Tech Forum.

Read the announcement
  • Josh Hanson speaking with a microphone at Octane’s Medical Innovation Forum
    Speaking · Oct. 27, 2026

    Josh Hanson speaks at Octane’s Medical Innovation Forum

    Partnership Pursuit session, Newport Beach, CA.

  • Phoenix Business Journal · 2026

    Josh Hanson named to the 2026 AZ Inno Under 25

    Named to the Phoenix Business Journal’s 2026 class of AZ Inno Under 25.

    Read the article
  • ASU News · Mar. 2026

    Selected for the 2026 Mayo Clinic and ASU Health Care Accelerator

    One of 10 companies from 6 nations in the 2026 cohort.

    Read on ASU News
  • AZBio · Oct. 7–8, 2026

    Presenting company at AZBio White Hat Investors 2026

    One of 32 companies selected by a panel of life science investors.

    See the list

Also in 2026

  • JuneSelected attending company, Mayo Clinic Cardiovascular Summit, Rochester, MN
  • Sept.Invited to the Society for Vascular Medicine annual meeting, Atlanta, GA
  • Sept.Joined Octane’s cardiovascular portfolio and was selected for Octane Medical Grand Rounds

Event photos © Octane / Michael Baker.

Contact

Interested in learning more?

We’re speaking with clinical partners, health systems, and investors. Tell us a little about yourself.

I’m reaching out as

Please don’t include patient or other protected health information.